Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease

Central Hospital, Nancy, France

Overview

Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. In patients with systemic sclerosis, interstitial lung disease (ILD) concerns almost 50 % of patients and represents the main cause of mortality. Janus kinases (JAK) inhibitors are recent therapies in the field of systemic autoimmune diseases, already approved in patients with rheumatoid arthritis. Use of JAK inhibitors in systemic sclerosis is based on their anti-inflammatory and anti-fibrotic properties. Several preclinical murine models of systemic sclerosis demonstrated the efficacy of ruxolitinib and tofacitinib on cutaneous and pulmonary fibrosis. Recently, tofacitinib was evaluated in SSc patients in two clinical studies and showed significant improvement on skin fibrosis. The objective of this study is to evaluate efficacy and safety of JAK inhibitors in SSc patients with ILD.

Study Type

OBSERVATIONAL

Conditions

Systemic Sclerosis Interstitial Lung Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with systemic sclerosis according to 2013 ACR/EULAR criteria * Patients with interstitial lung disease affecting at least 10 % of the lungs on HRCT chest, FVC of at least 40 % of the predicted value and DLCO between 30 % and 90 % of the predicted value * Use of JAK inhibitors Exclusion Criteria: * Patients with an alternative diagnosis of SSc-associated ILD (silicosis, sarcoidosis, lung cancer or other significant lung abnormalities) * Patients with pulmonary arterial hypertension defined on right heart catheterization

Locations (1)

CHU Nancy

Vandœuvre-lès-Nancy, Grand Est, France

Outcomes

Primary Outcomes

relative change in FVC after 12 months of JAK inhibitor

relative change in %predicted FVC after 12 months of JAK inhibitor

Time frame: at JAK inhibitor initiation (J0) and 12 months after JAK inhibitor initiation

Secondary Outcomes

relative change in DLCO after 12 months of JAK inhibitor

relative change in %predicted DLCO after 12 months of JAK inhibitor

Time frame: at JAK inhibitor initiation (J0) and 12 months after JAK inhibitor initiation

relative change in skin fibrosis after 12 months of JAK inhibitor

relative change in modified Rodnan skin score after 12 months of JAK inhibitor

Time frame: at JAK inhibitor initiation (J0) and 12 months after JAK inhibitor initiation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.